Non-alcoholic steatohepatitis in children

Pediatric Transplantation

Volumn 8, Issue 6, 2004, Pages 613-618

  Kerkar, Nanda ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Children; Insulin resistance; Non alcoholic fatty liver; Obesity

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMINOTRANSFERASE; BETAINE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; URSODEOXYCHOLIC ACID;

ACANTHOSIS NIGRICANS; AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHRONIC LIVER DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; DONOR; ECHOGRAPHY; FAMILY COUNSELING; FATTY LIVER; FIBROSIS; GLYCEMIC INDEX; HEALTH BEHAVIOR; HISPANIC; HISTOPATHOLOGY; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIVER BIOPSY; LIVER TRANSPLANTATION; LOW FAT DIET; OBESITY; PREPUBERTY; PROGNOSIS; RISK FACTOR; ULTRASOUND; WEIGHT REDUCTION;

ANIMALS; BIOPSY; CHILD; COMORBIDITY; DISEASE PROGRESSION; FATTY LIVER; HEPATITIS; HUMANS; LIVER; LIVER TRANSPLANTATION; OBESITY; PREVALENCE; RISK FACTORS;

EID: 11144235654     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2004.00241.x     Document Type: Conference Paper

References (59)

1. LUDWIG J, VIGGIANO TR, MCGILL DB, OH BJ. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980: 55: 434-438.
2. MORAN JR, GHISHAN FK, HALTER SA, GREENE HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 1983: 78: 374-377.
3. SANYAL A. Clinical features of NASH. Nonalcoholic Steatohepatitis Single Topic Conference, AASLD, Atlanta, GA, 2002: 14-19.
4. ALBERTI KG. Impaired glucose tolerance: what are the clinical implications? Diabetes Res Clin Pract 1998: 40(Suppl.): S3-S8.
5. KINUGASA A, TSUNAMOTO K, FURUKAWA N, SAWADA T, KUSUNOKI T, SHIMADA N. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr 1984: 3: 408-414.
6. FRANZESE A, VAJRO P, ARGENZIANO A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997: 42: 1428-1432.
7. STRAUSS RS, BARLOW SE, DIETZ WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000: 136: 727-733.
8. JAMES OF, DAY CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998: 29: 495-501.
9. ANGULO P, KEACH JC, BATTS KP, LINDOR KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999: 30: 1356-1362.
10. SINHA R, FISCH G, TEAGUE B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002: 346: 802-810.
11. DEFRONZO RA, TOBIN JD, ANDRES R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979: 237: E214-E223.
12. MATTHEWS DR, HOSKER JP, RUDENSKI AS, NAYLOR BA, TREACHER DF, TURNER RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985: 28: 412-419.
13. KATZ A, NAMBI SS, MATHER K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000: 85: 2402-2410.
14. MATHER KJ, HUNT AE, STEINBERG HO, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001: 86: 5457-5464.
15. MARCHESINI G, BRIZI M, MORSELLI-LABATE AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999: 107: 450-455.
16. LI Z, YANG S, LIN H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003: 37: 343-350.
17. WIGG AJ, ROBERTS-THOMSON IC, DYMOCK RB, MCCARTHY PJ, GROSE RH, CUMMINS AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001: 48: 206-211.
18. STRUBEN VM, HESPENHEIDE EE, CALDWELL SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000: 108: 9-13.
19. WILLNER IR, WATERS B, PATIL SR, REUBEN A, MORELLI J, RIELY CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001: 96: 2957-2961.
20. UYGUN A, KADAYIFCI A, YESILOVA Z, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000: 95: 3584-3589.
21. CHITTURI S, FARRELL G, FROST L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002: 36: 403-409.
22. DAY C. Genetic polymorphisms and susceptibility to liver inflammation in NASH and related diseases. Nonalcoholic Steatohepatitis Single Topic Conference, AASLD, Atlanta, GA, 2002: 77-85.
23. KERKAR N, AW MM, VERGANI D, MIELI-VERGANI G, BAKER AJ. Non-alcoholic fatty liver disease in children. J Paediatr Gastroenterol Nutr 2002: 34: 441.
24. SCHWIMMER JB, BURWINKLE TM, VARNI JW. Health-related quality of life of severely obese children and adolescents. JAMA 2003: 289: 1813-1819.
25. RASHID M, ROBERTS EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000: 30: 48-53.
26. SORBI D, BOYNTON J, LINDOR KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999: 94: 1018-1022.
27. SAKSENA SJO, CRAIG W, DAY C. Clinical and laboratory parameters predicting presence of NASH in unselected patients with NAFLD. Nonalcoholic Steatohepatitis Single Topic Conference, AASLD, Atlanta, GA, 2002: 143A.
28. LORIA PLA, FONTANA A, MURATORI P, et al. High prevalence of non-specific autoantibodies (NOSA) in NAFLD. J Hepatol 2002: 36: 21.
29. SAADEH S, YOUNOSSI ZM, REMER EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002: 123: 745-750.
30. BRUNT E. Pathology of nonalcoholic steatohepatitis. Non-alcoholic Steatohepatitis Single Topic Conference, AASLD, Atlanta, GA, 2002: 2-10.
31. American Gastroenterological Association. American Gastroenterological Association medical position statement on Obesity. Gastroenterology 2002: 123: 879-881.
32. VAJRO P, FONTANELLA A, PERNA C, ORSO G, TEDESCO M, DE VINCENZO A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994: 125: 239-241.
33. ROZENTAL P, BIAVA C, SPENCER H, ZIMMERMAN HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967: 12: 198-208.
34. ANDERSEN T, GLUUD C, FRANZMANN MB, CHRISTOFFERSEN P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991: 12: 224-229.
35. UENO T, SUGAWARA H, SUJAKU K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997: 27: 103-107.
36. SPIETH LE, HARNISH JD, LENDERS CM, et al. A low-glycemic index diet in the treatment of pediatric obesity. Arch Pediatr Adolesc Med 2000: 154: 947-951.
37. GOLDFIELD GS, EPSTEIN LH, KILANOWSKI CK, PALUCH RA, KOGUT-BOSSLER B. Cost-effectiveness of group and mixed family-based treatment for childhood obesity. Int J Obes Relat Metab Disord 2001: 25: 1843-1849.
38. LAURIN J, LINDOR KD, CRIPPIN JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996: 23: 1464-1467.
39. GUMA G, VIOLA L, THOME M, et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective controlled clinical trial. Hepatology 1997: 26: 386A.
40. CERIANI R, BUNATI S, MORINI L, et al. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis. A. Hepatology 1998: 28: 386
41. VAJRO P, FRANZESE A, VALERIO G, IANNUCCI MP, ARAGIONE N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000: 136: 739-743.
42. ABDELMALEK MF, ANGULO P, JORGENSEN RA, SYLVESTRE PB, LINDOR KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001: 96: 2711-2717.
43. BARAK AJ, BECKENHAUER HC, JUNNILA M, TUMA DJ. Dietary betaine promotes generation of hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration. Alcohol Clin Exp Res 1993: 17: 552-555.
44. LAVINE JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000: 136: 734-738.
45. GULBAHAR O. Treatment of non-alcoholic steatohepatitis with N-acetylcysteine. Gastroenterology 2000: 118: A1444.
46. LIN HZ, YANG SQ, CHUCKAREE C, KUHAJDA F, RONNET G, DIEHL AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000: 6: 998-1003.
47. MARCHESINI G, BRIZI M, BIANCHI G, TOMASSETTI S, ZOLI M, MELCHIONDA N. Metformin in non-alcoholic steatohepatitis. Lancet 2001: 358: 893-894.
48. HERMANNS-LE T, HERMANNS JF, PIERARD GE. Juvenile acanthosis nigricans and insulin resistance. Pediatr Dermatol 2002: 19: 12-14.
49. JONES KL, ARSLANIAN S, PETEROKOVA VA, PARK JS, TOMLINSON MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002: 25: 89-94.
50. NEUSCHWANDER-TETRI BA. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2002: 4: 31-36.
51. PROMRAT K, LUTCHMAN G, UWAIFO GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004: 39: 188-196.
52. MCCRINDLE BW, OSE L, MARAIS AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003: 143: 74-80.
53. MARSMAN WA, WIESNER RH, RODRIGUEZ L, et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996: 62: 1246-1251.
54. RINELLA ME, ALONSO E, RAO S, et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 2001: 7: 409-414.
55. CALDWELL SH, OELSNER DH, IEZZONI JC, HESPENHEIDE EE, BATTLE EH, DRISCOLL CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999: 29: 664-669.
56. CHARLTON MR, KONDO M, ROBERTS SK, STEERS JL, KROM RA, WIESNER RH. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg 1997: 3: 359-364.
57. SANJEEVI A, LYDEN E, SUNDERMAN B, WESEMAN R, ASHWATHNARAYAN R, MUKHERJEE S. Outcomes of liver transplantation for cryptogenic cirrhosis: a single-center study of 71 patients. Transplant Proc 2003: 35: 2977-2980.
58. MOLLOY RM, KOMOROWSKI R, VARMA RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 1997: 3: 177-178.
59. CONTOS MJ, CALES W, STERLING RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001: 7: 363-373.